Rosen Law Firm Urges Medpace Stockholders to Contact Firm

Lawsuit filed on behalf of Medpace Holdings, Inc. (NASDAQ: MEDP) stockholders who purchased shares between April 2025 and February 2026.

Apr. 8, 2026 at 12:32am

Got story updates? Submit your updates here. ›

A minimalist studio photograph featuring a stack of legal documents and a gavel on a clean, monochromatic background, conceptually representing the legal proceedings against Medpace.A class action lawsuit alleges Medpace made misleading statements that inflated its stock price, exposing the company to potential legal and financial risks.NYC Today

Rosen Law Firm, a global investor rights law firm, has announced a class action lawsuit on behalf of purchasers of common stock of Medpace Holdings, Inc. (NASDAQ: MEDP) between April 22, 2025 and February 9, 2026. Medpace is a clinical contract research organization (CRO) that provides outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries.

Why it matters

The lawsuit alleges that Medpace made false and misleading statements about its business, operations, and prospects during the class period, which artificially inflated the company's stock price. This could have significant financial implications for Medpace and its shareholders.

The details

The Rosen Law Firm is urging Medpace stockholders to contact the firm to learn more about their legal rights and options in the class action lawsuit.

  • The class period is from April 22, 2025 to February 9, 2026.

The players

Rosen Law Firm

A global investor rights law firm that has announced a class action lawsuit on behalf of Medpace stockholders.

Medpace Holdings, Inc.

A clinical contract research organization (CRO) that provides outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries.

Got photos? Submit your photos here. ›

The takeaway

This lawsuit highlights the potential legal risks and financial implications for public companies like Medpace if they are accused of making false or misleading statements that impact their stock price. Shareholders will be closely watching the outcome of this case.